Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug

Arrowhead Pharmaceuticals reported Phase 3 data for plozasiran showing 79-81% triglyceride reduction and 100% acute pancreatitis event reduction in severe hypertriglyceridemia patients, positioning it as potentially best-in-class against Ionis' recently approved Tryngolza. The company plans to file for FDA approval by year-end 2026.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.